Skin microbiome and acne vulgaris: Staphylococcus, a new actor in acne
Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 da...
Saved in:
Published in | Experimental dermatology Vol. 26; no. 9; pp. 798 - 803 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Wiley Subscription Services, Inc
01.09.2017
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo‐pustular lesions and non‐lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high‐throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under‐representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules (P=.004 and P=.003 respectively) than on non‐lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA‐2 and GEA‐3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic. |
---|---|
AbstractList | Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo-pustular lesions and non-lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high-throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under-representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules (P=.004 and P=.003 respectively) than on non-lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA-2 and GEA-3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic. Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo-pustular lesions and non-lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high-throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under-representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules (P=.004 and P=.003 respectively) than on non-lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA-2 and GEA-3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic. Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from come-dones, papulo-pustular lesions and non-lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high-throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under-representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, pap-ules and pustules (P=.004 and P=.003 respectively) than on non-lesional skin. Their proportions increased significantly with acne severity (P<.05 between GEA-2 and GEA-3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci. A significant reduction (P<.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic. Propionibacterium acnes ( P. acnes ), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This exploratory study investigated the characteristics of the skin microbiota in subjects with acne and determined microbiota changes after 28 days of application of erythromycin 4% or a dermocosmetic. Skin microbiota were collected under axenic conditions from comedones, papulo‐pustular lesions and non‐lesional skin areas from subjects with mild to moderate acne according to the GEA grading using swabs. Samples were characterized using a high‐throughput sequencing approach that targets a portion of the bacterial 16S rRNA gene. Overall, microbiota samples from 26 subjects showed an overabundance of Proteobacteria and Firmicutes and an under‐representation of Actinobacteria. Staphylococci were more abundant on the surface of comedones, papules and pustules ( P =.004 and P =.003 respectively) than on non‐lesional skin. Their proportions increased significantly with acne severity ( P <.05 between GEA‐2 and GEA‐3). Propionibacteria represented less than 2% of the bacteria on the skin surface. At Day 28, only the number of Actinobacteria had decreased with erythromycin while the dermocosmetic decreased also the number of Staphylococci . A significant reduction ( P <.05) from Day 0 of comedones, papules and pustules with no significant difference between the products was observed. The bacterial diversity on all sampling areas was similar. The dermocosmetic decreased the number of Actinobacteria and Staphylococcus spp. after 28 days. Staphylococcus remained the predominant genus of the superficial skin microbiota. No significant reduction in Staphylococcus spp. was observed with the topical antibiotic. |
Author | Dreno, Brigitte Henley, Jessica B. Martin, Richard Seité, Sophie Khammari, Amir Moyal, Dominique |
Author_xml | – sequence: 1 givenname: Brigitte surname: Dreno fullname: Dreno, Brigitte organization: CIC, Inserm U892‐CNRS 6299 – sequence: 2 givenname: Richard surname: Martin fullname: Martin, Richard organization: L'Oréal Research and Innovation – sequence: 3 givenname: Dominique surname: Moyal fullname: Moyal, Dominique organization: La Roche‐Posay Dermatological Laboratories – sequence: 4 givenname: Jessica B. surname: Henley fullname: Henley, Jessica B. organization: University of Colorado – sequence: 5 givenname: Amir surname: Khammari fullname: Khammari, Amir organization: CIC, Inserm U892‐CNRS 6299 – sequence: 6 givenname: Sophie orcidid: 0000-0001-9335-4139 surname: Seité fullname: Seité, Sophie email: sophie.seite@loreal.com organization: La Roche‐Posay Dermatological Laboratories |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28094874$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-01807656$$DView record in HAL |
BookMark | eNp10cFO3DAQBmALUcFCOfACVaReqERgbCeOzQ3RBSqt1AOtxM1yHLuYJvZiJ9B9-xp24YBaX-by_aPxzB7a9sEbhA4xnOD8Ts2f7gRTItgWmmEGUAIj9TaagQBWsgbqXbSX0j0AbmhT76BdwkFUvKlm6PLmt_PF4HQMrQuDKZTvCqW9KR6n_peKLp0VN6Na3q36oIPWUzouVOHNU0ZjiEUOP-uP6INVfTIHm7qPfl7Of1xcl4vvV98uzhelrgRmZZ5HCE2tZkoTowTu2poYbAVhlRXQ6KZhtKLGipYYRlvVas6s7VhrORYdofvoeN33TvVyGd2g4koG5eT1-UI6n0wcJGAODavZI878aM2XMTxMJo1ycEmbvlfehClJzBmuaw6EZvr5Hb0PU_T5MxILijmnHCCrTxs1tYPp3kZ4XWgGp2uQF5pSNFZqN6rRBT9G5XqJQT6fTOaTyZeT5cSXd4nXpv-ym-5Prjer_0M5v_26TvwF4QCi0A |
CitedBy_id | crossref_primary_10_1111_jdv_15795 crossref_primary_10_34172_jhp_2024_48170 crossref_primary_10_1111_exd_13791 crossref_primary_10_1111_exd_13397 crossref_primary_10_3389_fimmu_2023_1324930 crossref_primary_10_1111_srt_13269 crossref_primary_10_1097_BRS_0000000000005117 crossref_primary_10_1002_admi_202102261 crossref_primary_10_1007_s00005_018_0528_4 crossref_primary_10_3389_fcimb_2022_834135 crossref_primary_10_3390_jcm9010168 crossref_primary_10_1016_j_bbrc_2022_06_068 crossref_primary_10_1111_exd_13545 crossref_primary_10_1111_lam_13333 crossref_primary_10_2174_0126667797285930240306190539 crossref_primary_10_3390_microorganisms8111752 crossref_primary_10_1111_exd_13934 crossref_primary_10_1186_s12866_022_02477_2 crossref_primary_10_1186_s12934_022_01901_6 crossref_primary_10_25259_IJDVL_539_2024 crossref_primary_10_2147_CCID_S322876 crossref_primary_10_1007_s13555_024_01294_x crossref_primary_10_13181_mji_v28i1_2735 crossref_primary_10_2174_0126667797276773231215053914 crossref_primary_10_1016_j_jddst_2023_104149 crossref_primary_10_1111_jdv_20203 crossref_primary_10_1016_j_phymed_2022_154101 crossref_primary_10_3390_biomedicines10050931 crossref_primary_10_1016_j_meegid_2020_104209 crossref_primary_10_1007_s00248_022_02070_0 crossref_primary_10_3390_cosmetics10060150 crossref_primary_10_1111_exd_14105 crossref_primary_10_1016_j_heliyon_2024_e34549 crossref_primary_10_3390_ijms24032695 crossref_primary_10_3390_antibiotics12010145 crossref_primary_10_1038_s41598_022_25436_3 crossref_primary_10_3389_fimmu_2023_1151527 crossref_primary_10_3389_fmicb_2018_01459 crossref_primary_10_1007_s40257_020_00531_1 crossref_primary_10_3390_life11090962 crossref_primary_10_1051_e3sconf_202127103013 crossref_primary_10_1080_13102818_2021_1885992 crossref_primary_10_1080_09546634_2019_1628173 crossref_primary_10_1007_s12275_022_1520_6 crossref_primary_10_1111_jocd_16120 crossref_primary_10_1111_exd_14604 crossref_primary_10_1038_s41522_024_00512_w crossref_primary_10_2174_0118743722279314240219091938 crossref_primary_10_12677_ACM_2023_1361468 crossref_primary_10_1002_lsm_23426 crossref_primary_10_1002_jsfa_12921 crossref_primary_10_1016_j_jdsct_2024_100041 crossref_primary_10_1016_j_jaad_2023_12_017 crossref_primary_10_1080_10837450_2022_2038620 crossref_primary_10_3389_fmed_2023_1196149 crossref_primary_10_26724_2079_8334_2018_4_66_75_80 crossref_primary_10_3390_jcm8070987 crossref_primary_10_1111_bjd_19461 crossref_primary_10_1177_12034754211037994 crossref_primary_10_1016_j_ijpharm_2020_119074 crossref_primary_10_2478_am_2024_0009 crossref_primary_10_1016_j_annder_2018_11_002 crossref_primary_10_3390_cosmetics8030088 crossref_primary_10_1186_s41232_022_00212_y crossref_primary_10_3390_ph16010087 crossref_primary_10_1111_dth_15288 crossref_primary_10_2147_CCID_S474331 crossref_primary_10_12968_joan_2019_8_9_430 crossref_primary_10_1002_adfm_202421075 crossref_primary_10_2147_CCID_S379609 crossref_primary_10_3390_cosmetics9030055 crossref_primary_10_1111_jdv_17009 crossref_primary_10_3390_molecules29102394 crossref_primary_10_1111_exd_14433 crossref_primary_10_3389_fmicb_2022_1065386 crossref_primary_10_1111_exd_14951 crossref_primary_10_1155_2017_5095293 crossref_primary_10_21886_2308_6424_2023_11_3_118_130 crossref_primary_10_47419_bjbabs_v3i02_124 crossref_primary_10_3390_ijms22189846 crossref_primary_10_3389_fcimb_2025_1543616 crossref_primary_10_1002_jvc2_436 crossref_primary_10_1007_s11046_021_00586_6 crossref_primary_10_3390_microorganisms7110550 crossref_primary_10_1080_17512433_2020_1796637 crossref_primary_10_3389_fmicb_2018_02912 crossref_primary_10_3390_ijms232113071 crossref_primary_10_1016_j_jaad_2019_08_078 crossref_primary_10_3389_fcimb_2024_1307374 crossref_primary_10_3390_microorganisms9020303 crossref_primary_10_1111_exd_14779 crossref_primary_10_23736_S2724_5276_22_07010_0 crossref_primary_10_3390_microorganisms9112216 crossref_primary_10_21518_ms2023_264 crossref_primary_10_1007_s13555_022_00844_5 crossref_primary_10_1007_s00403_024_02836_1 crossref_primary_10_12688_f1000research_15659_1 crossref_primary_10_1080_14712598_2022_2089560 crossref_primary_10_1016_j_mucimm_2023_02_005 crossref_primary_10_1111_jdv_19540 crossref_primary_10_21518_2079_701X_2022_16_3_63_68 crossref_primary_10_4167_jbv_2017_47_3_165 crossref_primary_10_33667_2078_5631_2023_24_56_60 crossref_primary_10_1111_jdv_15043 crossref_primary_10_3390_app132112086 crossref_primary_10_3390_app14083505 crossref_primary_10_25279_sak_899794 crossref_primary_10_3839_jabc_2025_008 crossref_primary_10_1007_s12275_021_0647_1 crossref_primary_10_3389_fphar_2022_832088 crossref_primary_10_3390_pharmaceutics15082083 crossref_primary_10_1111_bcp_13662 crossref_primary_10_1111_exd_14535 crossref_primary_10_4103_ds_ds_28_22 crossref_primary_10_1016_j_jdermsci_2021_04_007 crossref_primary_10_1111_ijd_16220 crossref_primary_10_1186_s40168_018_0558_5 crossref_primary_10_1007_s40588_025_00243_2 |
Cites_doi | 10.1126/science.1260144 10.1111/1346-8138.13149 10.1186/s12864-016-2489-5 10.1111/ijd.12609 10.1038/nrmicro2537 10.1111/ajd.12253 10.1016/j.jid.2015.12.024 10.1128/JCM.00799-08 10.4049/jimmunol.169.3.1535 10.1111/exd.12206 10.1038/jid.2013.21 10.1111/j.1365-2133.1986.tb04060.x 10.1038/nature12171 10.1159/000087011 10.1007/s00253-013-5394-8 10.1111/bjd.14967 10.1093/bioinformatics/btq461 10.1128/AEM.00062-07 10.1186/gb-2012-13-11-r101 10.1111/1462-2920.12817 10.1126/science.1171700 10.1073/pnas.1000080107 10.12788/j.sder.0087 10.1155/2013/679680 10.1038/nmeth.2604 10.1371/journal.pone.0012277 10.1101/gr.096651.109 10.1016/j.jaad.2015.12.037 10.1590/0074-02760150356 10.1111/j.1468-3083.2010.03685.x 10.1159/000356777 10.1073/pnas.1424409112 10.1001/archderm.139.7.941-b 10.4103/0019-5154.174025 |
ContentType | Journal Article |
Copyright | 2017 The Authors. Published by John Wiley & Sons Ltd 2017 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd. 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Distributed under a Creative Commons Attribution 4.0 International License |
Copyright_xml | – notice: 2017 The Authors. Published by John Wiley & Sons Ltd – notice: 2017 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd. – notice: 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: Distributed under a Creative Commons Attribution 4.0 International License |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. NAPCQ 7X8 1XC VOOES |
DOI | 10.1111/exd.13296 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0625 |
EndPage | 803 |
ExternalDocumentID | oai_HAL_inserm_01807656v1 28094874 10_1111_exd_13296 EXD13296 |
Genre | article Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: La Roche‐Posay Dermatological Laboratory |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 24P 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7T5 H94 K9. NAPCQ 7X8 1XC VOOES |
ID | FETCH-LOGICAL-c4916-90699c3fc6ac2ea91db52e1f9264f907c776343ef9b2e63babc86ffd6bf819d23 |
IEDL.DBID | DR2 |
ISSN | 0906-6705 |
IngestDate | Fri May 09 12:20:41 EDT 2025 Thu Jul 10 17:23:03 EDT 2025 Fri Jul 25 09:53:41 EDT 2025 Mon Jul 21 05:41:52 EDT 2025 Thu Apr 24 23:02:07 EDT 2025 Tue Jul 01 01:14:46 EDT 2025 Wed Jan 22 16:34:11 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | microbiota Propionibacterium diversity acne skin microbiome Staphylococcus |
Language | English |
License | Attribution-NonCommercial-NoDerivs http://creativecommons.org/licenses/by-nc-nd/4.0 2017 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4916-90699c3fc6ac2ea91db52e1f9264f907c776343ef9b2e63babc86ffd6bf819d23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-9335-4139 0000-0001-9328-8004 0000-0001-5574-5825 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.13296 |
PMID | 28094874 |
PQID | 1931883800 |
PQPubID | 2045157 |
PageCount | 6 |
ParticipantIDs | hal_primary_oai_HAL_inserm_01807656v1 proquest_miscellaneous_1861558023 proquest_journals_1931883800 pubmed_primary_28094874 crossref_citationtrail_10_1111_exd_13296 crossref_primary_10_1111_exd_13296 wiley_primary_10_1111_exd_13296_EXD13296 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | September 2017 |
PublicationDateYYYYMMDD | 2017-09-01 |
PublicationDate_xml | – month: 09 year: 2017 text: September 2017 |
PublicationDecade | 2010 |
PublicationPlace | Denmark |
PublicationPlace_xml | – name: Denmark – name: Chichester |
PublicationTitle | Experimental dermatology |
PublicationTitleAlternate | Exp Dermatol |
PublicationYear | 2017 |
Publisher | Wiley Subscription Services, Inc Wiley |
Publisher_xml | – name: Wiley Subscription Services, Inc – name: Wiley |
References | 2015; 56 2015; 14 1986; 114 2003; 139 2013; 22 2005; 211 2016; 74 2011; 10 2005 2007; 73 2016; 18 2012; 202 2016; 17 2012; 13 2016; 12 2011; 9 2014; 228 2011; 108 2010; 26 2013; 10 2013; 2013 2002; 169 2015; 112 2016; 43 2013; 133 2016; 111 2009; 8 2013; 498 2008; 46 2016 2016; 61 2011; 25 2016; 136 2009; 19 2010; 5 2009; 324 2014; 346 2014; 33 2014; 98 2014; 53 e_1_2_7_6_1 Sanchez D. A. (e_1_2_7_5_1) 2015; 14 e_1_2_7_3_1 e_1_2_7_7_1 Domizio J. (e_1_2_7_4_1) 2016; 12 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 Bellew S. (e_1_2_7_8_1) 2011; 10 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 Chikviladze D. P. (e_1_2_7_41_1) 2012; 202 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 Wilson M. (e_1_2_7_30_1) 2005 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 Bhambri S. (e_1_2_7_9_1) 2009; 8 |
References_xml | – volume: 33 start-page: 98 year: 2014 publication-title: Semin. Cutan. Med. Surg. – volume: 74 start-page: e933 year: 2016 publication-title: J. Am. Acad. Dermatol. – volume: 43 start-page: 406 year: 2016 publication-title: J. Dermatol. – volume: 202 start-page: 60 year: 2012 publication-title: Georgian Med. News – volume: 108 start-page: 4516 issue: Suppl. 1 year: 2011 publication-title: Proc. Natl Acad. Sci. USA – year: 2005 – volume: 73 start-page: 5261 year: 2007 publication-title: Appl. Environ. Microbiol. – volume: 136 start-page: 621 year: 2016 publication-title: J. Invest. Dermatol. – volume: 8 start-page: 615 year: 2009 publication-title: J. Drugs Dermatol. – volume: 5 start-page: e12277 year: 2010 publication-title: PLoS ONE – volume: 114 start-page: 535 year: 1986 publication-title: Br. J. Dermatol. – volume: 13 start-page: R101 year: 2012 publication-title: Genome Biol. – volume: 46 start-page: 3355 year: 2008 publication-title: J. Clin. Microbiol. – volume: 61 start-page: 45 year: 2016 publication-title: Indian J. Dermatol. – volume: 26 start-page: 2460 year: 2010 publication-title: Bioinformatics – volume: 56 start-page: 268 year: 2015 publication-title: Australas. J. Dermatol. – volume: 112 start-page: E2120 year: 2015 publication-title: Proc. Natl Acad. Sci. USA – volume: 228 start-page: 86 year: 2014 publication-title: Dermatology – volume: 14 start-page: 127 year: 2015 publication-title: J. Drugs Dermatol. – volume: 211 start-page: 193 year: 2005 publication-title: Dermatology – volume: 22 start-page: 587 year: 2013 publication-title: Exp. Dermatol. – volume: 18 start-page: 1686 year: 2016 publication-title: Environ. Microbiol. – volume: 9 start-page: 244 year: 2011 publication-title: Nat. Rev. Microbiol. – volume: 12 start-page: 660 year: 2016 publication-title: Rev. Med. Suisse – year: 2016 publication-title: Br. J. Dermatol. – volume: 19 start-page: 2317 year: 2009 publication-title: Genome Res. – volume: 10 start-page: 582 year: 2011 publication-title: J. Drugs Dermatol. – volume: 25 start-page: 43 year: 2011 publication-title: J. Eur. Acad. Dermatol. Venereol. – volume: 10 start-page: 996 year: 2013 publication-title: Nat. Methods – volume: 17 start-page: 152 year: 2016 publication-title: BMC Genom. – volume: 98 start-page: 411 year: 2014 publication-title: Appl. Microbiol. Biotechnol. – volume: 133 start-page: 2152 year: 2013 publication-title: J. Invest. Dermatol. – volume: 139 start-page: 941 year: 2003 publication-title: Arch. Dermatol. – volume: 111 start-page: 155 year: 2016 publication-title: Mem. Inst. Oswaldo Cruz – volume: 53 start-page: 1177 year: 2014 publication-title: Int. J. Dermatol. – volume: 498 start-page: 367 year: 2013 publication-title: Nature – volume: 346 start-page: 954 year: 2014 publication-title: Science – volume: 324 start-page: 1190 year: 2009 publication-title: Science – volume: 2013 start-page: 679680 year: 2013 publication-title: Biomed. Res. Int. – volume: 169 start-page: 1535 year: 2002 publication-title: J. Immunol. – ident: e_1_2_7_18_1 doi: 10.1126/science.1260144 – ident: e_1_2_7_38_1 doi: 10.1111/1346-8138.13149 – ident: e_1_2_7_21_1 doi: 10.1186/s12864-016-2489-5 – ident: e_1_2_7_19_1 doi: 10.1111/ijd.12609 – ident: e_1_2_7_2_1 doi: 10.1038/nrmicro2537 – ident: e_1_2_7_6_1 doi: 10.1111/ajd.12253 – ident: e_1_2_7_33_1 doi: 10.1016/j.jid.2015.12.024 – ident: e_1_2_7_32_1 doi: 10.1128/JCM.00799-08 – volume: 8 start-page: 615 year: 2009 ident: e_1_2_7_9_1 publication-title: J. Drugs Dermatol. – ident: e_1_2_7_10_1 doi: 10.4049/jimmunol.169.3.1535 – ident: e_1_2_7_12_1 doi: 10.1111/exd.12206 – ident: e_1_2_7_13_1 doi: 10.1038/jid.2013.21 – ident: e_1_2_7_15_1 doi: 10.1111/j.1365-2133.1986.tb04060.x – ident: e_1_2_7_31_1 doi: 10.1038/nature12171 – ident: e_1_2_7_11_1 doi: 10.1159/000087011 – ident: e_1_2_7_22_1 doi: 10.1007/s00253-013-5394-8 – ident: e_1_2_7_7_1 doi: 10.1111/bjd.14967 – volume: 14 start-page: 127 year: 2015 ident: e_1_2_7_5_1 publication-title: J. Drugs Dermatol. – ident: e_1_2_7_27_1 doi: 10.1093/bioinformatics/btq461 – ident: e_1_2_7_28_1 doi: 10.1128/AEM.00062-07 – ident: e_1_2_7_34_1 doi: 10.1186/gb-2012-13-11-r101 – ident: e_1_2_7_24_1 doi: 10.1111/1462-2920.12817 – ident: e_1_2_7_3_1 doi: 10.1126/science.1171700 – ident: e_1_2_7_25_1 doi: 10.1073/pnas.1000080107 – ident: e_1_2_7_29_1 doi: 10.12788/j.sder.0087 – ident: e_1_2_7_36_1 doi: 10.1155/2013/679680 – ident: e_1_2_7_26_1 doi: 10.1038/nmeth.2604 – volume-title: Microbial Inhabitants of Humans: Their Ecology and Role in Health and Disease year: 2005 ident: e_1_2_7_30_1 – ident: e_1_2_7_14_1 doi: 10.1371/journal.pone.0012277 – ident: e_1_2_7_20_1 doi: 10.1101/gr.096651.109 – volume: 10 start-page: 582 year: 2011 ident: e_1_2_7_8_1 publication-title: J. Drugs Dermatol. – volume: 12 start-page: 660 year: 2016 ident: e_1_2_7_4_1 publication-title: Rev. Med. Suisse – ident: e_1_2_7_37_1 doi: 10.1016/j.jaad.2015.12.037 – ident: e_1_2_7_40_1 doi: 10.1590/0074-02760150356 – ident: e_1_2_7_23_1 doi: 10.1111/j.1468-3083.2010.03685.x – ident: e_1_2_7_35_1 doi: 10.1159/000356777 – volume: 202 start-page: 60 year: 2012 ident: e_1_2_7_41_1 publication-title: Georgian Med. News – ident: e_1_2_7_17_1 doi: 10.1073/pnas.1424409112 – ident: e_1_2_7_16_1 doi: 10.1001/archderm.139.7.941-b – ident: e_1_2_7_39_1 doi: 10.4103/0019-5154.174025 |
SSID | ssj0017375 |
Score | 2.5215094 |
Snippet | Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This... Propionibacterium acnes ( P. acnes ), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne.... Propionibacterium acnes (P. acnes), the sebaceous gland and follicular keratinocytes are considered the three actors involved in the development of acne. This... |
SourceID | hal proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 798 |
SubjectTerms | Acne Acne Vulgaris - drug therapy Acne Vulgaris - microbiology Adolescent Adult Anti-Bacterial Agents - administration & dosage Cancer Comedones diversity Double-Blind Method Erythromycin Erythromycin - administration & dosage Female Fish Humans Keratinocytes Life Sciences Male microbiome microbiota Microbiota - drug effects Next-generation sequencing Propionibacterium rRNA 16S Sebaceous gland Skin Skin - microbiology Skin diseases Staphylococcus Staphylococcus - isolation & purification Young Adult |
Title | Skin microbiome and acne vulgaris: Staphylococcus, a new actor in acne |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.13296 https://www.ncbi.nlm.nih.gov/pubmed/28094874 https://www.proquest.com/docview/1931883800 https://www.proquest.com/docview/1861558023 https://inserm.hal.science/inserm-01807656 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB_aPogvWr9Xa4mi4IN77CbZ3USfivY4xIqIhXsQlnzSQ2-v9G5L6V_fSfYD6weIbwuZsNlMJvObzeQ3AC8ctSU6ZpYan_GUS8dSyU2RKs68zRSVPvJsH30qZ8f8w7yYb8Hb4S5Mxw8x_nALlhH362DgSq9_MnJ3YSehSnqg2w65WgEQfRmpo_KKRZLdTGLEXFZZ0bMKhSyesec1X7R9EjIhf4eZ11FrdDvT2_BtGHCXbfJ90m70xFz-wuX4n1-0C7d6OEoOuvVzB7ZccxduHPUH7vdgGopzkeWio2taOqIaS5RpHDlvwyWQxfoNQbyKukKnuDKmXb8miiBUJ7GOD8HOQfo-HE8Pv76bpX3phdRwBIwpzpqUhnlTKkOdkrnVBXW5l4ifPMbTpsJ9iTPnpaauZFppI0rvbak9QgxL2QPYaVaNewSkEtqKQmMgZjTPOFeMYSRcFNbluhBUJvBqUEJtel7yUB7jRz3EJzgvdZyXBJ6PoqcdGcefhF6iJsf2QJ89O_hYLxo06WUd-MoqxLDneQJ7g67r3m7XNcLZXAiGKDqBZ2MzWlw4RlGNW7UoI8JZbiDOS-Bht0bGt1GB4bKoOH5U1PTfh1kfzt_Hh8f_LvoEbtKAKmKK2x7sbM5a9xQx0Ubvwzbln_ejCVwBM_wFHg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD60FdQX79bRqlEUfHCWmUnmEvGl2C6r7vZBWtgXCbnSRXe2dHeK-Os9yVywXkB8G8gJk-TkJN9JTr4D8MJmpsCNmcbaJSxm3NKYM53HklFnEplxF3i2Z0fF5IR9mOfzLXjbv4Vp-SGGAzdvGWG99gbuD6R_snL7zYx8mvRiG674jN6eOf_g00AelZY00OwmHH3mokzyjlfIx_EMVS_tRtunPhbyd6B5GbeGjWd8Ez73TW7jTb6Mmo0a6e-_sDn-b59uwY0OkZL9dgrdhi1b34Grs-7O_S6MfX4usly0jE1LS2RtiNS1JReNfweyWL8hCFlRXbgvrrRu1q-JJIjWSUjlQ7Cyl74HJ-PD43eTuMu-EGuGmDHGYeNcU6cLqTMreWpUntnUcYRQDl1qXeLSxKh1XGW2oEoqXRXOmUI5RBkmo_dhp17V9gGQslKmyhX6YlqxhDFJKTrDeW5sqvIq4xG86rUgdEdN7jNkfBW9i4LjIsK4RPB8ED1r-Tj-JPQSVTmUewbtyf5ULGq06qXwlGUlwtiLNIK9XtmiM921QESbVhVFIB3Bs6EYjc7fpMjarhqUqfx1rufOi2C3nSTD37IKPeaqZNipoOq_N1Mczg_Cx8N_F30K1ybHs6mYvj_6-AiuZx5khIi3PdjZnDf2MUKkjXoSLOEHXCsIYw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB71IVVcKigFAqWYikocCEpsJ7HhVLVdLfShHqi0N8tPsRKbrbrdip_P2MlGVIDELZLHSjKTsb_JjL8BeOepq3FjZrkNBc-59CyX3Fa55iy4QlMZEs_2xWU9vuZfJ9VkDT6vzsJ0_BDDD7foGWm9jg5-48JvTu5_uo-xS3q9Dpsx2RfruSi_GlIIDUssu4XEkLluiqqnFYplPMPUB5vR-vdYCvknznwIW9O-M3oM2z1gJEedhZ_Amm93YOuiT4k_hVFsn0Vm045QaeaJbh3RtvXkfhmPaUwXnwgiStQmbltza5eLD0QTBNMkddohODlK78L16PTb8TjvmyPkliOky_G1pLQs2Fpb6rUsnamoL4NEhBMw4rUNrhyc-SAN9TUz2lhRh-BqExAEOMqewUY7b_0LII0wTlQGQyVreMG5Zgxj1apyvjSVoDKD9ystKdszh8cGFj_UKoJAhaqk0AwOBtGbji7jb0KHqOphPBJcj4_O1bRFp5upyCjWIMq8LzPYWxlD9Z61UAg4SyEY4twM3g7D6BMx0aFbP1-ijIjZ1khtl8HzzojD3ajAgFY0HF8qWfXfj6lOJyfp4uX_i76BrauTkTr_cnn2Ch7RCAFSPdoebNzdLv1rBDB3Zj99qL8AOcbmyw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Skin+microbiome+and+acne+vulgaris%3A+Staphylococcus%2C+a+new+actor+in+acne&rft.jtitle=Experimental+dermatology&rft.au=Dreno%2C+Brigitte&rft.au=Martin%2C+Richard&rft.au=Moyal%2C+Dominique&rft.au=Henley%2C+Jessica+B.&rft.date=2017-09-01&rft.issn=0906-6705&rft.eissn=1600-0625&rft.volume=26&rft.issue=9&rft.spage=798&rft.epage=803&rft_id=info:doi/10.1111%2Fexd.13296&rft.externalDBID=10.1111%252Fexd.13296&rft.externalDocID=EXD13296 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0906-6705&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0906-6705&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0906-6705&client=summon |